구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Natural Killer (NK, Natural Killer, Natural Killer (NK) Lymphocytes) National Cancer Institute (NCI)·Metastatic Melanoma 84 trials·t½ 34 h |
|---|---|
Overview Program | Natural Killer (NK) Lymphocytes |
Overview Company | National Cancer Institute (NCI) |
Overview Modality | CGT |
Overview Target | Metastatic Melanoma |
Overview Indication | Metastatic Melanoma; Metastatic Kidney Cancer |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
PK/PD Half-life | 34 h |
Toxicology Major finding | Polysaccharides: Natural candidates for targeting immunometabolic regulation in hepatocellular carcinoma (Review).. Hepatocellular carcinoma (HCC) is a leading cause of cancer‑related morbidity and mortality worldwide. HCC pathogenesis is predominantly associated with chronic liver disease, driven by a vicious cycle of persistent hepatic injury, chronic inflammation and aberrant hepatocyte … |
Toxicology CRS | Reported |
Clinical Safety signal | Polysaccharides: Natural candidates for targeting immunometabolic regulation in hepatocellular carcinoma (Review).. Hepatocellular carcinoma (HCC) is a leading cause of cancer‑related morbidity and mortality worldwide. HCC pathogenesis is predominantly associated with chronic liver disease, driven by a vicious cycle of persistent hepatic injury, chronic inflammation and aberrant hepatocyte … |
Clinical Reported ORR | 0% |
Clinical Result source | ClinicalTrials.gov NCT00328861 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT00328861 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Natural Killer (NK, Natural Killer, Natural Killer (NK) Lymphocytes) National Cancer Institute (NCI)·Metastatic Melanoma 84 trials·t½ 34 h |
|---|---|
Overview Program | Natural Killer (NK) Lymphocytes |
Overview Company | National Cancer Institute (NCI) |
Overview Modality | CGT |
Overview Target | Metastatic Melanoma |
Overview Indication | Metastatic Melanoma; Metastatic Kidney Cancer |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
PK/PD Half-life | 34 h |
Toxicology Major finding | Polysaccharides: Natural candidates for targeting immunometabolic regulation in hepatocellular carcinoma (Review).. Hepatocellular carcinoma (HCC) is a leading cause of cancer‑related morbidity and mortality worldwide. HCC pathogenesis is predominantly associated with chronic liver disease, driven by a vicious cycle of persistent hepatic injury, chronic inflammation and aberrant hepatocyte … |
Toxicology CRS | Reported |
Clinical Safety signal | Polysaccharides: Natural candidates for targeting immunometabolic regulation in hepatocellular carcinoma (Review).. Hepatocellular carcinoma (HCC) is a leading cause of cancer‑related morbidity and mortality worldwide. HCC pathogenesis is predominantly associated with chronic liver disease, driven by a vicious cycle of persistent hepatic injury, chronic inflammation and aberrant hepatocyte … |
Clinical Reported ORR | 0% |
Clinical Result source | ClinicalTrials.gov NCT00328861 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT00328861 |
추천 비교
추천 비교